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Abstract
Successful curative treatment of severe pulmonary arterial hypertension with luminal obliteration will require a thorough
understanding of the mechanism underlying the development and progression of pulmonary vascular lesions. But the cells
that obliterate the pulmonary arterial lumen in severe pulmonary arterial hypertension are incompletely characterized. The
goal of our study was to evaluate whether inhibition of CXC chemokine receptor 4 will prevent the accumulation of c-kit+
cells and severe pulmonary arterial hypertension. We detected c-kit+- cells expressing endothelial (von Willebrand Factor) or
smooth muscle cell/myofibroblast (a-smooth muscle actin) markers in pulmonary arterial lesions of SU5416/chronic hypoxia
rats. We found increased expression of CXC chemokine ligand 12 in the lung tissue of SU5416/chronic hypoxia rats. In our
prevention study, AMD3100, an inhibitor of the CXC chemokine ligand 12 receptor, CXC chemokine receptor 4, only
moderately decreased pulmonary arterial obliteration and pulmonary hypertension in SU5416/chronic hypoxia animals.
AMD3100 treatment reduced the number of proliferating c-kit+ a-smooth muscle actin+ cells and pulmonary arterial
muscularization and did not affect c-kit+ von Willebrand Factor+ cell numbers. Both c-kit+ cell types expressed CXC
chemokine receptor 4. In conclusion, our data demonstrate that in the SU5416/chronic hypoxia model of severe pulmonary
hypertension, the CXC chemokine receptor 4-expressing c-kit+ a-smooth muscle actin+ cells contribute to pulmonary
arterial muscularization. In contrast, vascular lumen obliteration by c-kit+ von Willebrand Factor+ cells is largely independent
of CXC chemokine receptor 4.
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Introduction
Severe pulmonary arterial hypertension (PAH) is characterized
by a lumen-obliterating pulmonary microvasculopathy and
complex, multicellular plexiform lesions [1]. These vascular
lesions and abnormal vessel tone lead to increased pulmonary
vascular resistance and right heart failure [2]. Endothelial cell (EC)
apoptosis-dependent compensatory cell overgrowth appears to be
an important confounding cause of lumen obliteration in severe
PAH [3,4]. Additional factors that are likely pathobiologically
relevant, are mutations in the bone morphogenic protein receptor
2 and inflammation [5]._ENREF_6 However, the nature and the
origin of the phenotypically altered and proliferating cells that
occlude the pulmonary vascular lumen are incompletely under-
stood.
Progenitor cells are non-terminally differentiated cells with the
potential to undergo proliferation and terminal differentiation
[6,7]. Bone marrow (BM)-derived endothelial progenitor cells
(EPCs) may contribute to neoangiogenesis [8]. Stem- and
progenitor cell niches, harboring EPCs, hematopoietic progenitor
cells and mesenchymal stem cells have been identified in the vessel
wall of the systemic circulation [9]. One way to identify progenitor
cells in addition to their proliferative capacity is the use of cellular
markers that are not expressed by terminally differentiated cells,
such as c-kit, a tyrosine kinase receptor for stem cell factor. c-kit
has been originally detected on the surface of embryonic stem
cells, primitive hematopoietic cells and mast cells, and signaling via
c-kit is important for hematopoiesis and vascular development
[10,11]. In the human lung, c-kit+ stem cells can repopulate
airways and vessels [12] and a recent study has identified that
mouse lung ECs contain a c-kit+ population of rare vascular
endothelial stem cells that can generate functional blood vessels
[13].
The accumulation of stem and progenitor cells at sites of injury
requires CXC chemokine receptor 4 (CXCR4), a G-protein
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coupled receptor for CXC chemokine ligand 12 (CXCL12).
CXCR4 is expressed on progenitor and stem cells, phagocytic cells
of the innate immune system and tumor cells [14]. Signaling via
CXCR4 is important for migration of circulating and resident cells
towards a CXCL12 gradient, as well as for cell survival and
proliferation [14]. Activation of the CXCL12/CXCR4 axis
contributes to the repair of the ischemic myocardium [15].
CXCR4 and its ligand CXCL12 have been identified in plexiform
lesions of patients with advanced PAH [15,16]._ENREF_17
However, the potential relevance of this signaling pathway for
the development of lumen-obliterating pulmonary arterial lesions
remains unclear.
Inhibition of CXCR4 in chronically hypoxic mice prevents the
accumulation of c-kit+ putative HPCs in pulmonary arteries and
the development of pulmonary hypertension [17,18]. We hypoth-
esized that c-kit+ cells, including c-kit+ progenitor cells, accumulate
in and around the lumen-occluding lesions of pulmonary arteries
in severe PAH and that severe PAH and accumulation of c-kit+
cells depends on CXCR4.
In our study, we show the spatiotemporal localization of c-kit+
cells in the pulmonary vascular lesions from rats with SU5416/
chronic hypoxia (SuHx)-induced angioobliterative PAH [4]. Our
work extends previous experimental studies by demonstrating that
some c-kit+ cells in the pulmonary arteries express endothelial and
vascular smooth muscle cell (VSMC)/myofibroblast markers.
Having found elevated CXCL12 protein levels in the lungs of
SuHx animals, we examined the effects of the CXCR4 inhibitor
AMD3100 in the SuHx model. We demonstrate that AMD3100
treatment prevented pulmonary arterial muscularization, but only
partially reduced the pulmonary arterial obliteration. The overall
result was a moderate reduction in pulmonary hypertension.
CXCR4 blockade reduced the total number of c-kit+ cells and
CXCR4+ cells, in particular the number of c-kit+ a-smooth muscle
actin (a-SMA)+ cells, CXCR4+ a-SMA+ and proliferating c-kit+ a-
SMA+ cells.
Materials and Methods
Animal experiments
All animal experiments were approved by the institutional
animal care and utilization committee of Virginia Commonwealth
University, Richmond, VA (Protocol number AM10157). This
study was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. All surgery was performed under
Ketamine/Xylazine anesthesia, and all efforts were made to
minimize suffering. SuHx-induced severe angioobliterative PAH
was established by a single subcutaneous injection of 20 mg?kg21
SU5416 at day 0 and exposure to chronic hypoxia for up to 28
days, followed by housing under normoxic conditions for
experiments with a total duration of 42 days [4,19,20]. The
animals were euthanized at the given time points by exsanguina-
tion following hemodynamic measurements [19] and blood
sampling. Lung and heart were removed en bloc, and the right
lung was snap frozen for molecular biology studies. The left lung
was inflated with 0.5% low-melting agarose (20 cmH2O) and
formalin-fixed (48 h), then paraffin-embedded for Elastica van
Gieson (EvG) staining, immunohistochemistry (IHC) and immu-
nofluorescence (IF) staining, as well as in situ hybridization. Naı¨ve
control animals were housed at room air. SuHx animals received
5 mg?kg21?day21 AMD3100 (Tocris Bioscience, Ellisville, MI) or
vehicle (PBS) intraperitoneally from day 1–21. At day 21, the
animals were euthanized for tissue harvest.
Histology
Paraffin-embedded and formalin-fixed lung tissue was sectioned
at a thickness of 3 mm. EvG staining was performed as published
previously [21]. For vascular histomorphometry, images of EvG-
stained sections were randomly taken with an AXIO imager.A1
microscope, Axiocam HRc camera and Axiovision software (all
Zeiss, Jena, Germany) at 1006 magnification. Each animal
received a numeric code to ensure objectivity. Media thickness
(MT) and external diameter (ED) were measured by an
investigator blinded to the treatment groups as published before
and media wall thickness (MWT) was calculated according to the
formula: MWT (%) = [2 6 (MT?ED21)] 6 100% [21].
Pulmonary arteries were categorized according to their size as
follows: small: 25 mm,ED,50 mm, medium size: 50 mm #
ED,100 mm. For each animal, 30–40 pulmonary arteries were
measured in two orthogonal directions using ImageJ [22].
For vWF IHC, 3 mm sections were rehydrated, followed by
antigen retrieval using enzymatic digestion (proteinase K, 1:50,
DAKO, Carpinteria, CA) for 6 min in PBS. Then, endogenous
peroxidase (3% H2O2 in PBS) was blocked for 5 min and
unspecific interactions were inhibited with 1% normal swine
serum (NSS) for 15 min. The sections were incubated with the
primary antibody (anti-vWF A008202, DAKO, dilution 1:5000,)
in 1% NSS/PBS overnight at 4uC and with the secondary, biotin-
conjugated antibody (AP132B, Millipore, Billierica, MA, dilution
1:1500) in 1%NSS/PBS for 1 h at room temperature. This was
followed by 45 min incubation with HRP-conjugated Streptavidin
in 1%NSS/PBS (dilution 1:200, Vector Laboratories, Burlingame,
CA), counterstaining with Mayer’s Hematoxylin, dehydration and
mounting.
For IF stainings, 3 mm sections were rehydrated, followed by
antigen retrieval with heat in citrate buffer pH 6.0 for 20 min.
Then, sections were blocked with 1% NSS/PBS for 15 min and
incubated with primary antibody #1 in 1% NSS in PBS overnight
at 4 uC. Sections were then incubated with the secondary antibody
#1 in PBS for 4 h. For double and triple IF stainings, additional
sequential incubations were performed with primary and second-
ary antibody #2 (and #3 for triple IF) similar to #1. Finally, the
sections were counterstained with 4’,6-diamidino-2-phenylindole
(DAPI) 1:20000 for 5 min and mounted in Slow Fade Gold (both
Life Technologies/Invitrogen, Carlsbad, CA). The following
primary antibodies were used: a-SMA (C6198, Sigma-Aldrich,
St. Louis, MO, dilution 1:200, no secondary antibody as this
antibody is directly Cy3-conjugated) or (M0851, DAKO, dilution
1:200, no label), c-kit (LS-C78828, LifeSpan Biosciences, Seattle,
WA, dilution 1:50), CXCR4 #1 (ab2074, Abcam, Cambridge,
MA, dilution 1:50), CXCR4 #2 (ab1671, Abcam, dilution 1:25),
mast cell tryptase (IMG-80250, Imgenex, San Diego, CA, dilution
1:20), PCNA (#2586, Cell Signaling Technology, Danvers, MA,
dilution 1:100), vWF (A008202, DAKO, dilution 1:50). The
following secondary antibodies were used: A11058 (Life Technol-
ogies/Invitrogen, dilution 1:50), A21202 (Life Technologies/
Invitrogen, dilution 1:100), A21203 (Life Technologies/Invitro-
gen, dilution 1:100), A21121 (Life Technologies/Invitrogen,
dilution 1:50), A21131 (Life Technologies/Invitrogen, dilution
1:50), A21442 (Life Technologies/Invitrogen, dilution 1:100),
A21443 (Life Technologies/Invitrogen, dilution 1:50). For all IHC
and IF stainings, controls with unspecific IgG were run in parallel
with each staining batch and treatment group.
In situ hybridization
5 mm thick formalin-fixed, paraffin-embedded lung tissue
sections were used for in situ hybridization with the QuantiGene
ViewRNA ISH Tissue Assay kit (Affymetrix, Cleveland, OH)
CXCR4 Inhibition and Severe Pulmonary Hypertension
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according to the manufacturer’s instructions. Custom TYPE1
QuantiGene View RNA probes were obtained from Affymetrix for
rat Kit (Gen Bank Accession number NM_022264, region 501–
1476 covered by probeset). Pretreatment was performed for 10
min at 95uC and protease digestion for 20 min at 40uC. TYPE1
probes were stained with Fast red and counterstained with Gill’s
Hematoxylin. A negative control (probe omitted) was run in
parallel (Figure S1). Images were taken with AXIO imager.A1
microscope, Axiocam HRc camera and Axiovision software (all
Zeiss)
Quantification of IHC and IF stainings
For the quantification of vascular obliteration in vWF-stained
sections, 15 images were randomly acquired for each animal from
2 transversal sections through the left lung (one at the level of the
hilum, one at least 200 mm caudal of the hilum) at a magnification
of 1006, containing .80 pulmonary arteries of different calibers.
The images were obtained with an AXIO imager.A1 microscope,
Axiocam HRc camera and Axiovision software. Each animal
received a number code to ensure objectivity. For each pulmonary
artery, an investigator blinded to the treatment groups classified
the degree of occlusion as none, partial or complete, and measured
the ED.
For quantification of double IF stainings, red, green and blue
fluorescence channel images were acquired of 10–15 randomly
selected pulmonary arteries from 2 transversal sections through the
left lung (one at the level of the hilum, one at least 200 mm caudal
of the hilum) for each animal at a magnification of 4006with an
IX70 fluorescence microscope, XM10 camera and Cellsens
software (all Olympus). For triple IF stainings, 10 randomly
selected pulmonary arteries from 2 transversal sections through the
left lung were acquired at a magnification of 6306 with a laser
scanning confocal microscope using specific filters for DAPI,
AlexaFluor 488, 594 and 647 (see below). The images of each
animal received a unique numeric code to ensure objectivity. The
number of c-kit+, CXCR4+, vWF+ c-kit+, vWF+ CXCR4+, a-
SMA+ c-kit+, a-SMA+ CXCR4+, PCNA+ c-kit+, PCNA+ c-kit+
vWF+ and PCNA+ c-kit+ a-SMA+ cells per pulmonary artery
(lumen/lumen-occluding cells, cells in intima, media, adventitia
and perivascular infiltrate) was counted in the assembled
multichannel image using the cell counter plugin of ImageJ by
an investigator blinded to the treatment groups.
Figure 1. Accumulation of c-kit+ cells in the SU5416/chronic hypoxia (SuHx) model. (A) Representative images of in situ hybridization
images demonstrating Kit mRNA expression. In naı¨ve control animals, occasional low Kit expression was found in cells of vessels and alveolar walls,
whereas multiple cells in lumen-obliterating regions and vessel wall/perivascular region expressed Kit (granular staining pattern) in the lung of a SuHx
animal. The open arrows indicate cells with strong Kit expression. Counterstaining with Gill’s Hematoxylin. Magnification: 4006. Scale bar: 20 mm. (B)
Quantification of the number of c-kit+ cells/vessel over time. n = 3 animals per group. * P,0.05, ** P,0.01. (C) Images demonstrate representative
optical sections (confocal microscopy). c-kit+, c-kit+ von Willebrand Factor+ (vWF+) and c-kit+ a-smooth muscle actin+ (a-SMA+) cells were occasionally
found in alveolar walls and vessel walls of naı¨ve control animals. c-kit+ and c-kit+ a-SMA+ cells accumulated in and around the pulmonary arteries of
SuHx animals over time. The number of c-kit+ vWF+ cells also increased until day 21 in and around the pulmonary arteries of SuHx animals and started
to decline thereafter. Arrows indicate c-kit+ vWF+ or c-kit+ a-SMA+ cells. Nuclear counterstaining with 4’,6-diamidino-2-phenylindole (DAPI).
Magnification: 6306. Scale bar: 20 mm. (D-E) Quantification of the number of c-kit+ vWF+ (D) and c-kit+ a-SMA+ (E) cells per vessel. n = 3 animals per
group. * P,0.05, ** P,0.01 and *** P,0.0001.
doi:10.1371/journal.pone.0089810.g001
CXCR4 Inhibition and Severe Pulmonary Hypertension
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Confocal microscopy
Confocal microscopy was performed with a Leica TCS SP2
laser scanning confocal microscopy system or a Zeiss LSM 700
laser scanning confocal microscope system housed in the VCU
Department of Anatomy and Neurobiology Microscope Facility. If
confocal imaging was done in addition to widefield microscopy,
the sections used for confocal microscopy were serial sections of
the ones used for widefield microscopy and quantification.
Protein lysate preparation and Western blot
One whole right lobe was homogenized in radioimmunopre-
cipitation assay (RIPA) buffer (tissue to buffer ratio: 0.3 g?ml21)
(Sigma Aldrich) supplemented with protease- and phosphatase-
inhibitors (Roche Diagnostics, Indianapolis, IN; Sigma Aldrich;
New England Biolabs, Ipswich, MA). After 30 min of incubation in
RIPA buffer, lung protein lysate was centrifuged at 13,0006g for
10 min and the supernatant stored at –80uC. Protein concentra-
tion was determined by Bio-Rad Protein Assay (Bio-Rad). The
protein lysate was incubated for 10 min at 70uC in SDS loading
buffer (Santa Cruz Biotechnology) and 50 mg protein was loaded
into each well for SDS-PAGE. After electrophoresis, proteins were
blotted onto a PVDF membrane (Bio-Rad), blocked for 1 h in 5%
dry milk-PBS-0.1% Tween 20 (blocking buffer) and incubated
with the respective primary antibodies overnight at 4uC in
blocking buffer: cleaved caspase-3 (#9661, Cell Signaling Tech-
nologies, dilution 1:1000), CXCL12 (sc-28876, Santa Cruz,
dilution 1:200), PCNA (#2586, Cell Signaling Technologies,
dilution 1:1000), b-actin (A5441, Sigma-Aldrich, dilution 1::00).
Secondary HRP-conjugated antibodies were applied for 1 h at
room temperature in blocking buffer. The blots were developed
with ECL reagent (PerkinElmer, Waltham, MA) on Genemate X-
ray films (BioExpress, Kaysville, UT).
Figure 2. c-kit+ cells in the angioobliterative lesions were not
mast cells. Representative optical section obtained by confocal
microscopy demonstrates the presence of mast cells (c-kit+ mast cell
tryptase+, arrows) around the airway mucosa of SU5416/chronic
hypoxia (SuHx) animal at day 21 (positive control). In a naı¨ve control
lung, only one isolated c-kit+ mast cell tryptase2 cell was present in the
pulmonary artery (open arrow). One cell with faint granular green
autofluorescence (likely a macrophage) was present in the alveolar
space (double-headed arrow). No mast cells were seen in the lumen-
obliterating lesions of SuHx animals at day 21, only c-kit+ mast cell
tryptase2 cells (open arrows). A single cell with faint granular green
autofluorescence was seen in the alveolar space, likely a macrophage
(double-headed arrow). Nuclear counterstaining: 4’,6-diamidino-2-phe-
nylindole (DAPI). Magnification: 6306. Scale bar: 20 mm.
doi:10.1371/journal.pone.0089810.g002
Figure 3. CXC chemokine receptor 4 (CXCR4) and CXC chemokine ligand 12 (CXCL12) expression. (A) Representative
immunofluorescence stainings for CXCR4 and von Willebrand Factor (vWF) showing that while CXCR4 was found on vWF+ endothelial cells
(arrow), perivascular cells and cells in the alveolar walls in the lungs of control animals, there was an increase in CXCR4 expression in luminal, vessel
wall and perivascular cells with multiple CXCR4+ vWF+ cells (arrows) in the lumen of the pulmonary artery in the lungs of SuHx animals. Please note
that the vessel shown in the image of SuHx day 6 was sectioned transversally, whereas the vessels in the images of SuHx day 21 and 42 were
sectioned in a more longitudinal manner. Nuclear staining with 4’,6-diamidino-2-phenylindole (DAPI). Magnification: 6306. Scale bar: 20 mm. (B)
Representative Western blot analysis indicates that the protein expression of the CXCR4 ligand CXCL12 was increased in SuHx lung tissue protein
lysate as compared to naı¨ve control animals. b-actin was used as loading control. (C) Densitometry of the Western blot in (B). Densitometric values
were normalized vs. b-actin and expressed as n-fold of naı¨ve controls. n = 3 animals per group. * P,0.05.
doi:10.1371/journal.pone.0089810.g003
CXCR4 Inhibition and Severe Pulmonary Hypertension
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Statistical analysis
Data are presented as mean 6 SEM. The groups were
compared with 2-tailed unpaired Student’s t test (2 groups) or 1-
way ANOVA followed by a multiple comparison test according to
Newman-Keuls (.2 groups). Statistics and graphs were done with
GraphPad Prism 5.0 (GraphPad Software). P,0.05 was consid-
ered significant.
Results
c-kit+ cells accumulated in experimental
angioobliterative PAH
First, the spatiotemporal distribution of cells expressing c-kit was
examined in the lung of control and SuHx animals by in situ
hybridization and IF staining. Then, it was investigated whether
these c-kit+ cells express the EC marker vWF and the VSMC/
myofibroblast marker a-SMA. In-situ hybridization and IF staining
revealed that rare c-kit+ cells were localized in the alveolar walls
and pulmonary arteries, in particular in the intima, media and
adventitia layers of naı¨ve control rats, and that some of these c-kit+
cells also expressed either the EC marker vWF or the VSMC/
myofibroblast marker a-SMA (Figure 1). In the lungs of SuHx
animals, an accumulation of c-kit+ cells was detected as early as
day 6 and the vascular aggregates of c-kit+ cells were most
extensive at day 21 and 42 (Figure 1). There was a progressive
accumulation of c-kit+ vWF+ cells until day 21 and of c-kit+ a-
SMA+ cells until day 42 (Figure 1C-E). Co-staining of c-kit with
mast cell tryptase was used to investigate whether the lung vascular
lesion c-kit+ cells were mast cells [17]. c-kit+ mast cell tryptase+
cells were not detected in and around the obliterated pulmonary
arteries of SuHx animals (Figure 2).
Lung tissue expression of CXCR4 and lung protein levels
of CXCL12 in SuHx animals
In naı¨ve control animals, CXCR4+ vWF+ ECs and CXCR4+
cells were identified in the pulmonary artery wall and perivascular
region, as well as in the alveolar walls (Figure 3A). In SuHx
animals, CXCR4+ cells accumulated in the lumen, pulmonary
artery wall and perivascular region over time (Figure 3A). The
protein expression of the CXCR4 ligand CXCL12 was increased
at day 6, 21 and 42 in the lung tissue protein lysate of SuHx
animals (Figure 3B-C).
Expression of CXCR4, vWF and a-SMA in c-kit+ cells in
SuHx animals
In order to investigate whether various c-kit+ cells express
CXCR4 and may therefore be a valid target for CXCR4
inhibition, the expression profile of CXCR4, vWF and a-SMA
Figure 4. Expression of CXC chemokine receptor 4 (CXCR4) and von Willebrand Factor (vWF) in c-kit+ cells. Representative optical
sections obtained by confocal microscopy demonstrating the co-expression of CXCR4, vWF and c-kit in the pulmonary artery wall of a naı¨ve animal
and in pulmonary vascular lesion cells of animals with SU541/chronic hypoxia (SuHx) induced severe PAH. The inserts show the area outlined by a box
in more detail. Arrows indicate triple positive cells in the inserts. Nuclear counterstaining: 4’-6-diamidino-2-phenylindole (DAPI). Magnification: 4006.
Scale bar: 20 mm.
doi:10.1371/journal.pone.0089810.g004
CXCR4 Inhibition and Severe Pulmonary Hypertension
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e89810
was determined in c-kit+ cells by triple IF stainings and confocal
microscopy. The concomitant expression of CXCR4, vWF and c-
kit was not detected in pulmonary arteries of naı¨ve animals (Figure
4). In SuHx animals, multiple CXCR4+ vWF+ c-kit+ cells were
found in pulmonary arterial lesions of SuHx animals at day 21 and
42 (Figure 4). Co-expression of the three markers CXCR4, a-SMA
and c-kit was also not identified in pulmonary arteries of naı¨ve
animals (Figure 5). In contrast, multiple CXCR4+ a-SMA+ c-kit+
cells were detected in the obliterated pulmonary arteries of SuHx
animals at day 21 and 42 (Figure 5).
CXCR4 inhibition prevented the increased
muscularization and partially the obliteration of
pulmonary arteries in the SuHx model
To address the question whether CXCR4 signaling contributes
to the lung vascular lesion formation, SuHx rats were treated with
the CXCR4 inhibitor AMD3100. AMD3100 treatment moder-
ately reduced the right ventricular (RV) systolic pressure (RVSP)
and RV hypertrophy. AMD3100 treatment further completely
prevented the increase in average pulmonary artery MWT, a
measure of pulmonary arterial muscularization (Figure 6).
CXCR4 inhibition only partially prevented the obliteration of
small and medium-sized pulmonary arteries as assessed by vWF
IHC (Figure 6).
CXCR4 inhibition reduced lung cell proliferation and
decreased the presence of c-kit+ cells
AMD3100 treatment significantly reduced the protein expres-
sion of PCNA and cleaved caspase-3 in the lung tissue protein
lysate of SuHx animals (Figure 7A-C). These findings were
associated with the decreased presence of c-kit+ cells and c-kit+ a-
SMA+ cells in and around pulmonary arteries, but not with a
reduction in the number of c-kit+ vWF+ cells in pulmonary arteries
(Figure 8A-B). Less PCNA+ cells, c-kit+ PCNA+ cells and c-kit+ a-
SMA+ PCNA+ were found in and around pulmonary arteries
following AMD3100 treatment, but a significant reduction in the
number of c-kit+ vWF+ PCNA+ cells was not detected (Figure 8A,
C). These results indicate that the number and the proliferation of
these c-kit+ vWF+ cells were not affected by CXCR4 inhibition.
Hence, the reduced proliferation of primitive a-SMA+ c-kit+ cells
after AMD3100 treatment correlated with the prevention of
increased muscularization in pulmonary arteries.
The accumulation of vWF+ CXCR4+ cells was not
significantly reduced by AMD3100
AMD3100 treatment reduced the total number of CXCR4+
cells and CXCR4+ a-SMA+ per vessel in the pulmonary arteries of
SuHx animals, but there was only a small trend towards reduced
Figure 5. Expression of CXC chemokine receptor 4 (CXCR4) and a-smooth muscle actin (a-SMA) in c-kit+ cells. Representative optical
sections obtained by confocal microscopy demonstrating the co-expression of CXCR4, a-SMA and c-kit in the pulmonary artery of a naı¨ve animal and
in pulmonary vascular lesion cells of animals with SU5416/chronic hypoxia (SuHx) induced severe PAH. The inserts show the area outlined by a box in
more detail. Arrows indicate triple positive cells in the inserts. Nuclear counterstaining: 49-6-diamidino-2-phenylindole (DAPI). Magnification: 4006.
Scale bar: 20 mm.
doi:10.1371/journal.pone.0089810.g005
CXCR4 Inhibition and Severe Pulmonary Hypertension
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e89810
number of CXCR4+ vWF+ cells after AMD3100 treatment (Figure
9A-C).
Discussion
The pathophysiology of severe PAH has been traditionally
explained largely as a consequence of chronic hemodynamic
stress, such as pulmonary vasoconstriction and elevated shear
stress [23]. The increase in the pulmonary vascular resistance is
now also attributed to the structural alterations of the pulmonary
arteries and reversal of these structural changes has become a
treatment goal [2]. Successful and permanent reversal of the
pulmonary arterial remodeling will likely require a detailed
knowledge of the altered microenvironment of the remodeled
pulmonary artery [2]. The early phase of lung vessel disease
development in human PAH remains unexamined and it is not
feasible to serially study diseased human lungs. Hence, we
investigated the development of vascular obliteration in an animal
model of severe PAH that predictably generates obliterative
Figure 6. AMD3100 prevented severe pulmonary arterial hypertension (PAH) in the SU5416/chronic hypoxia (SuHx) model. (A)
Representative von Willebrand Factor (vWF) immunohistochemistry indicates the occlusion of pulmonary arteries (arrows). These images
demonstrate that treatment with the CXC chemokine receptor 4 inhibitor AMD3100 only partially prevented the obliteration of pulmonary arteries.
Counterstaining: Mayer’s Hematoxylin. Magnification: 1006. Scale bar: 100 mm. (B) Reduced right ventricular systolic pressure (RVSP) and (C)
decreased right ventricle (RV)/(left ventricle [LV]+Septum) ratio. (D) Reduced pulmonary arterial muscularization (external diameter [ED] ,100 mm)
was detected after AMD3100 treatment. (E-F) The degree of obliteration of pulmonary arteries in AMD3100-treated SuHx animals was partially
reduced for small (E) (25 mm,ED,50 mm) and for medium-sized (F) (50 mm # ED,100 mm) pulmonary arteries. (B-F): n = 6 animals per group. *
P,0.05, ** P,0.01, *** P,0.0001.
doi:10.1371/journal.pone.0089810.g006
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pulmonary arterial lesions resembling those observed in the lungs
of patients with severe PAH [4,24].
The pulmonary vascular lesions in severe PAH are complex and
multicellular, and it has been suggested that the lesions contain
primitive angiogenic cells that express endothelial markers [25].
Indeed, a variety of stem and progenitor cell markers has been
detected in vascular lesions of patients with severe PAH
[16,17,26]. BM-derived progenitors from PAH patients can
induce vascular remodeling, including in situ thrombi, in the
pulmonary arteries of mice [27]._ENREF_15_ENREF_30 In the
present study, we concentrated on the role of cells expressing the
tyrosine kinase receptor c-kit: c-kit is a common marker of
primitive progenitor and stem cells, including the recently
described lung stem cells [12] and rare vascular endothelial stem
cells [13]. c-kit+ mast cells and c-kit+ progenitor cells have also
been identified in pulmonary vascular lesions of patients with
severe PAH [17,26] and around pulmonary arteries of chronic
hypoxic mice [18].
The main findings of our experimental studies are: 1) c-kit+ cells
accumulate in and around the pulmonary artery lesions in the
SuHx model of severe obliterative PAH. 2) Some c-kit+ cells
express endothelial and mesenchymal markers. 3) CXCR4+ cells
accumulate in the pulmonary vascular lesions of SuHx animals
and the CXCR4 ligand CXCL12 is found at elevated protein
levels in the lung tissue of SuHx animals. 4) c-kit+ cells in the
pulmonary vascular lesions frequently express CXCR4. 5)
CXCR4 blockade affects c-kit+ cell participation, in particular
the proliferation of a-SMA+ c-kit+ cells, and pulmonary arterial
muscularization. 6) Occlusion of pulmonary arteries and severe
PAH were only partially prevented by CXCR4 blockade. 7)
CXCR4+ a-SMA+ cells, but not CXCR4+ vWF+ cells, were
reactive to AMD3100 treatment.
Similar to human PAH [17,26], we identified in our study in the
lungs of the animals with severe SuHx-induced PAH c-kit+ cells
within the lumen-occluding cells and in the perivascular cellular
aggregates. We extend the current knowledge of the presence of c-
kit+ cells in pulmonary vascular lesions by demonstrating that the
c-kit+ cells found in the pulmonary vascular lesions are not a
uniform population: Some c-kit+ cells in the pulmonary arterial
wall expressed the endothelial marker vWF or the VSMC/
myofibroblast marker a-SMA. c-kit expression has been demon-
strated on a variety of cell types, including mast cells, dendritic
cells, pre-T and pre-B lymphocytes, hematopoietic progenitor and
stem cells, as well as various forms of tissue-derived progenitor and
stem cells [12,13,17,28]. As expected, a small number of c-kit+
cells were also detected in the pulmonary arteries and alveolar
walls from control animals. The population of c-kit+ cells, and in
particular the pool of c-kit+ vWF+ and c-kit+ a-SMA+ cells, was
vastly expanded in and around the pulmonary arterial lesions of
SuHx animals. It is interesting that the presence of c-kit+ vWF+
cells started to decline after day 21 in the SuHx model. At the
same time, c-kit+ a-SMA+ cell continued to accumulate in the
remodeled pulmonary arteries and were also increasingly found
among lumen-obliterating cells. One possible explanation is the
transdifferentiation of c-kit+ EPCs into a-SMA expressing VSMC
or myofibroblast precursors in more mature lesions, a process that
has been already suggested in vitro [29-31]. Because a-SMA
expression is also frequently found in activated myofibroblasts in
Figure 7. Proliferation and apoptosis in the lungs of AMD3100-treated SU5416/chronic hypoxia (SuHx) animals. (A) Representative
Western blot for proliferating cell nuclear antigen (PCNA) and cleaved caspase-3 in the lung tissue protein lysate of naı¨ve control animals (n = 3), SuHx
+ vehicle (n = 6) and SuHx + AMD3100 treated rats (n = 6). b-actin was used as loading control. (B-C) Densitometric analysis indicates increased PCNA
(B) and cleaved caspase-3 (C) protein levels in the lungs of SuHx + vehicle animals vs. controls, and that AMD3100 treatment significantly reduced
PCNA and cleaved caspase-3 protein levels in the lungs of SuHx animals. Densitometric values were normalized vs. b-actin and expressed as n-fold of
naı¨ve controls. n = 3 animals per group for controls and n = 6 animals per group for SuHx + vehicle and SuHx + AMD3100 groups. * P,0.05 and **
P,0.01.
doi:10.1371/journal.pone.0089810.g007
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scar tissue, the c-kit+ a-SMA+ may also represent myofibroblast
precursors [32,33] that accumulate in the obliterated pulmonary
arteries during a process of intravascular scar formation.
Fibrocytes, which are characterized as cells expressing hemato-
poietic and mesenchymal markers, have been identified as an
important source of myofibroblasts in the context of lung fibrosis
[34-36]. Because fibrocytes express markers of immature hema-
topoietic cells, such as CD34, it is possible that at least a fraction of
the c-kit+ cells, the c-kit+ a-SMA+ cells, represents fibrocytes
[34,35]. Fibrocytes have been suggested to contribute to pulmo-
nary vascular remodeling in mice, rats and calves under conditions
Figure 8. Proliferation of c-kit+ cells in the lungs of AMD3100-treated SU5416/chronic hypoxia (SuHx) animals. (A) Representative
optical sections (confocal microscopy) demonstrate c-kit+ von Willebrand Factor+ (vWF+) proliferating cell nuclear antigen+ (PCNA+) cells (upper row)
or c-kit+ a-smooth muscle actin+ (a-SMA+) PCNA+ cells (lower row) in pulmonary arteries of SuHx + vehicle and SuHx + AMD3100 treated animals. The
inserts show a triple positive cell (arrow) in more detail. Please note that the bright white stained dots indicate cells with very strong PCNA staining.
Nuclear counterstaining: 4’,6-diamidino-2-phenylindole (DAPI). Magnification: 6306. Scale bar: 20 mm. (B-C) Quantification of the number of c-kit+, c-
kit+ vWF+ and c-kit+ a-SMA+, as well as PCNA+, c-kit+ PCNA+, c-kit+ vWF+ PCNA+ and c-kit+ a-SMA+ PCNA+ cells in and around the pulmonary arteries of
SuHx + vehicle and SuHx + AMD3100 animals. n = 3 animals per group. * P,0.05 and ** P,0.01.
doi:10.1371/journal.pone.0089810.g008
Figure 9. Effect of AMD3100 treatment on CXC chemokine receptor 4+ (CXCR4+) cells. Quantification of the number of total CXCR4+ cells
(A), CXCR4+ von Willebrand Factor+ (vWF+) cells (B) and CXCR4+ a-smooth muscle actin+ (a-SMA+) cells (C) per vessel in pulmonary arteries of SuHx
animals treated with vehicle or AMD3100. The data indicate that while the number of total CXCR4+ cells and CXCR4+ a-SMA+ cells per vessel was
significantly reduced by AMD3100 treatment, there was only a small trend towards decreased number of CXCR4+ vWF+ cells per vessel in AMD3100
treated SuHx animals. n = 4 animals/group. * P,0.05, *** P,0.0001.
doi:10.1371/journal.pone.0089810.g009
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of chronic hypoxia [33,37] and fibrocytes may also contribute to
pulmonary vascular remodeling in severe obliterative PAH.
The receptor for CXCL12, CXCR4, is important for the
homing of stem and progenitor cells to sites of tissue injury [38].
CXCR4 is expressed in the lung vascular lesions of patients with
severe PAH [16,26]. Therefore, we investigated the expression of
CXCR4 and CXCL12 in the lungs of SuHx animals. We found
CXCR4 expression in the cells that accumulated over time in the
lumen, pulmonary artery wall and perivascular region of SuHx
animals. CXCR4 expression was also frequently detected in c-kit+
cells, including the c-kit+ vWF+ and c-kit+ a-SMA+ cells that
clustered in and around the remodeled pulmonary arteries of
SuHx animals. Because the accumulation of CXCR4+ cells is
directed by the tissue expression of its ligand CXCL12 [39], it is
not surprising that the expression of the CXCR4 ligand CXCL12
was significantly increased in the lung tissue of SuHx animals. The
expression of CXCL12 is extensively regulated by tissue hypoxia
and by local tissue injury [36,40]. We suggest that the upregulation
of CXCL12 in the lungs of SuHx animals is likely dependent on
chronic hypoxia, as demonstrated in chronic hypoxic mice
[18,41], and the ongoing vascular injury originally initiated by
injection of SU5416 [3,29]. The increased expression of CXCL12,
the accumulation of CXCR4+ cells and the expression of CXCR4
in the c-kit+ cells in the lung vascular lesions provided the rationale
to investigate whether the formation of lesions in the pulmonary
arteries was dependent on CXCL12/CXCR4.
CXCR4 inhibition with AMD3100 reduced the accumulation
and proliferation of c-kit+ cells and the muscularization of the
remodeled pulmonary arteries from SuHx animals. The main
effect was decreased proliferation of c-kit+ a-SMA+ cells, a finding
that provides a cellular correlate to the morphologically reduced
muscularization of pulmonary arteries. Our findings in a rat model
of severe, obliterative PAH complement recent work in chronic
hypoxic mice indicating that c-kit+ cells may contribute to
pulmonary arterial muscularization in a CXCR4-dependent
manner [18]. The findings that c-kit+ a-SMA+ cells express
CXCR4 and accumulate in a CXCR4-dependent manner in the
remodeled pulmonary arteries further support the concept that
these c-kit+ a-SMA+ CXCR4+ cells may be fibrocytes that
contribute to pulmonary vascular remodeling. Various studies
have shown that CXCR4 inhibition reduces lung fibrosis via
reduced fibrocyte migration [36,42,43]. However, in SuHx
animals, CXCR4 inhibition only caused a modest reduction in
PAH and did not significantly decrease the number of c-kit+ vWF+
or proliferating c-kit+ vWF+ cells in pulmonary arteries. Our data
also indicate that the accumulation of CXCR4+ vWF+ ECs/EPCs
is largely independent of CXCR4, in contrast to the accumulation
of CXCR4+ cells and CXCR4+ a-SMA+ cells. We propose that
the cells retained in the obliterated pulmonary arteries may
represent a c-kit+ EPC pool, that was largely unaffected by
AMD3100. We base our assumption on the localization of the cells
in the lumen obliterating lesions and the co-expression of the EC
marker vWF with c-kit in these cells [13]. It is possible that
CXCR4 inhibition may not only decrease homing of circulating
cells, but may also reduce migration of lung resident cells or
impact the function of stem/progenitor cells [44,45]._ENREF_56
Because AMD3100 does not affect the c-kit+ vWF+ cells, we
propose that these c-kit+ vWF+ cells are likely lung resident EPCs
and/or that their migration and homing is not critically dependent
on CXCR4 [13,18,29,36,46]. Our data indicate that lumen
obliteration by vWF+ cells may be promoted by mechanisms in
addition to CXCL12/CXCR4 signaling. One example of such an
additional mechanism may be the increased expression of the pro-
angiogenic factor fibroblast growth factor 2. Fibroblast growth
factor 2 has been shown to be elevated in pulmonary arterial
lesions of PAH patients and animals with SuHx-induced severe
PAH [47,48].
The reduction in RVSP following CXCR4 inhibition was only
moderate in SuHx rats – in contrast to the studies conducted in the
chronic hypoxic model of PAH. Our data suggest that the
persistent RVSP elevation can be explained, similar to concepts in
human severe PAH, by the residual obliteration of pulmonary
arteries that was only partially prevented by CXCR4 blockade [2].
The data further indicate that the arteriolar occlusion is due to a
different set of c-kit+ cells, likely EPCs, that seem to be largely
unaffected by AMD3100 treatment.
In conclusion, our data indicate that c-kit+ progenitor cells
accumulate in and around the lung vascular lesions of SuHx rats.
Our data also suggest that in severe experimental PAH, lung
vascular obliteration and the accumulation of c-kit+ cells only
partially depend on CXCR4 activity. In contrast, CXCR4
signaling is required for pulmonary arterial muscularization. c-
kit+ a-SMA+ cells appear to contribute to pulmonary arterial
muscularization in a CXCR4-dependent manner. A different
subset of c-kit+ cells with endothelial markers seems to contribute
to pulmonary arterial obliteration in a largely CXCR4-indepen-
dent fashion. Whether c-kit+ progenitor cell populations are
sufficient to cause obliterative pulmonary vascular disease or
whether additional factors are required will have to be examined
by cell transfer experiments.
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Figure S1 Negative control for in situ hybridization.
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4006. Scale bar: 20 mm.
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